Literature DB >> 8806641

Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis.

S K Banerjee1, K Bhatt, S Rana, P Misra, P K Chakraborti.   

Abstract

A wild type strain of Mycobacterium smegmatis mc2 155 was serially adapted to 64 fold of minimal inhibitory concentration of an antimycobacterial agent, ciprofloxacin. This clone (CIPr) exhibited cross resistance to ofloxacin and ethidium bromide. The rate of drug efflux was accelerated in CIPr compared to the wild type strain. Verapamil, a calcium channel blocker, enhanced the drug accumulation in CIPr by diminishing the efflux and thus reversed the resistant phenotype. Additionally, a missense mutation was detected in the quinolone resistance determining region of the DNA-gyrase A subunit of CIPr. Taken together, these results suggest that drug efflux plays a major role in conferring such a high level of resistance in CIPr, in addition to the mutation in the DNA-gyrase locus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806641     DOI: 10.1006/bbrc.1996.1362

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

3.  Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism.

Authors:  Fernanda S Spies; Pedro E Almeida da Silva; Marta O Ribeiro; Maria Lucia Rossetti; Arnaldo Zaha
Journal:  Antimicrob Agents Chemother       Date:  2008-06-09       Impact factor: 5.191

Review 4.  Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Authors:  Philippa A Black; Robin M Warren; Gail E Louw; Paul D van Helden; Thomas C Victor; Bavesh D Kana
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

5.  Study of efflux pump gene expression in rifampicin-monoresistant Mycobacterium tuberculosis clinical isolates.

Authors:  Guilian Li; Jingrui Zhang; Qian Guo; Jianhao Wei; Yi Jiang; Xiuqin Zhao; Li-Li Zhao; Zhiguang Liu; Jianxin Lu; Kanglin Wan
Journal:  J Antibiot (Tokyo)       Date:  2015-02-18       Impact factor: 2.649

6.  Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Authors:  Alexandra Aubry; Xiao-Su Pan; L Mark Fisher; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

7.  Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates.

Authors:  Mradula Singh; G P S Jadaun; K Srivastava; Vipin Chauhan; Ritu Mishra; Kavita Gupta; Surya Nair; D S Chauhan; V D Sharma; K Venkatesan; V M Katoch
Journal:  Indian J Med Res       Date:  2011-05       Impact factor: 2.375

8.  A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism.

Authors:  Ujjini H Manjunatha; Anthony Maxwell; Valakunja Nagaraja
Journal:  Nucleic Acids Res       Date:  2005-06-01       Impact factor: 16.971

9.  Resistance in tuberculosis: what do we know and where can we go?

Authors:  Keith D Green; Sylvie Garneau-Tsodikova
Journal:  Front Microbiol       Date:  2013-07-23       Impact factor: 5.640

10.  The drug resistance profile of Mycobacterium abscessus group strains from Korea.

Authors:  Seung Heon Lee; Hee Kyung Yoo; Seol Hee Kim; Won-Jung Koh; Chang Ki Kim; Young Kil Park; Hee Jin Kim
Journal:  Ann Lab Med       Date:  2013-12-06       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.